Abstract
We report the preliminary results of a prospective study demonstrating technetium(III)-99m furifosmin (Q12) uptake in histologically proven parathyroid adenomas. Scintigraphy was performed in 12 patients with hyperparathyroidism. Q12 correctly identified the parathyroid adenomas by focal prolonged tracer retention in ten of the 12 patients. In the two patients without localized tracer retention, no parathyroid adenoma could be identified surgically, either. The retention half-times ranged from 0.5 to 1.8 h (mean 1.27) in the parathyroid adenomas and from 0.3 to 1.2 h (mean 1.05) in the thyroid gland. Our preliminary results show that Q12 is a feasible, sensitive tracer for parathyroid scintigraphy. In comparison to sestamibi (MIBI) and tetrofosmin, Q12 displays short retention in the thyroid gland, which would seem rather advantageous. Further evaluation is needed to determine which among Q12, tetrofosmin and MIBI is most sensitive for the detection especially of small parathyroid adenomas, and which tracer properties will best reflect the degree of endocrine activity.
This is a preview of subscription content, log in via an institution to check access.
References
Gerson MC, Lukes J, Deutsch E, Biniakiewicz D, Rohe RC, Washburn LC, Fortman C, Walsh RA. Comparison of technetium 99mQ12 and thallium 201 for detection of angiographically documented coronary artery disease in humans.J Nucl Cardiol 1994; 1: 499–508.
Deutsch E, VanderHeyden J, Gerundi P, Libson K, Hirth W, Colombo F, Savi A, Fazio F. Development of non-reducible technetium 99m(III) cations as myocardial perfusion imaging agents, initial experience in humans.J Nucl Med 1987; 28: 1870–1880.
Gerson MC, Millard RW, Roszell NJ, et al.. Kinetic properties of Tc99mQ12 in canine myocardium.Circulation 1994; 89: 1291–1300.
Hendel RC, Parker MA, Wackers FJ, Rigo P, Lahiri A, Zaret BL. Reduced variability of interpretation and improved image quality with a technetium 99m myocardial perfusion agent: comparison of thallium 201 and technetium 99m-labeled tetrofosmin.J Nucl Cardiol 1994; 1: 509–514.
Rossetti C, Vanoli G, Paganelli G, et al.. Human biodistribution, dosimetry and clinical use of technetium (III)-99m-Q12.J Nucl Med 1994; 35: 1571–1580.
Coakley AJ, Kettle AG, Wells CP, O'Doherty, Collins RE. 99Tc sestamibi — a new agent for parathyroid imaging.Nucl Med Commun 1989; 10: 791–794.
Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study).J Nucl Med 1992; 33: 1801–1807.
O'Doherty JO, Kettle AG, Wells P, et al. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies.J Nucl Med 1992; 33: 313–318.
Osmanagaoglu K, Schelstraete K, Lippens M, Obrie E, De Feyter I. Visualization of a parathyroid adenoma with Tc-99m MIBI in a case with iodine saturation and impaired thallium uptake.Clin Nucl Med 1993; 18: 214–216.
Aigner RM, Fueger GF, Nicoletti R. Parathyroid scintigraphy: comparison of technetium-99m methoxyisobutylisonitrile and technetium-99m tetrofosmin studies.Eur J Nucl Med 1996; 23: 693–696.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aigner, R.M., Fueger, G.F. & Wolf, G. Parathyroid scintigraphy: First experiences with technetium(III)-99m-Q12. Eur J Nucl Med 24, 326–329 (1997). https://doi.org/10.1007/BF01728772
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01728772